Výsledky vyhledávání

Akademický článek

Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.

Autor: McLaughlin V; Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA vmclaugh@umich.edu., Channick RN; Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, USA., Ghofrani HA; University of Giessen and Marburg Lung Center, Giessen, Germany., Lemarié JC; Department of Statistics, Effi-Stat, Paris, France., Naeije R; Department of Cardiology, Erasme University Hospital, Brussels, Belgium., Packer M; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA., Souza R; Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, Brazil., Tapson VF; Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Tolson J; Global Medical Affairs, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland., Al Hiti H; Department of Cardiology, IKEM, Prague, Czech Republic., Meyer G; Complexo Hospitalar Santa Casa De Porto Alegre, Pulmonary Vascular Research Institute, Porto Alegre, Brazil., Hoeper MM; Department of Respiratory Medicine, Hannover Medical School and German Center of Lung Research (DZL), Hannover, Germany.

Publikováno v: The European respiratory journal [Eur Respir J] 2015 Aug; Vol. 46 (2), pp. 405-13. Date of Electronic Publication: 2015 Jun 25.

Zobrazit plný text záznamu

Akademický článek

Validation of two predictive models for survival in pulmonary arterial hypertension.

Autor: Sitbon O; Université Paris-Sud, CHU de Bicêtre, INSERM U999, Le Kremlin Bicêtre, France Both authors contributed equally olivier.sitbon@bct.aphp.fr., Benza RL; The Cardiovascular Institute, West Penn Allegheny Health System, Pittsburgh, PA, USA Both authors contributed equally., Badesch DB; Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO, USA., Barst RJ; Columbia University College of Physicians and Surgeons, New York, NY, USA., Elliott CG; Intermountain Medical Center and the University of Utah, Salt Lake City, UT, USA., Gressin V; Actelion Pharmaceuticals France, Paris, France., Lemarié JC; Effi-stat, Paris, France., Miller DP; ICON Clinical Research, San Francisco, CA, USA., Muros-Le Rouzic E; Actelion Pharmaceuticals, Allschwil, Switzerland., Simonneau G; Université Paris-Sud, CHU de Bicêtre, INSERM U999, Le Kremlin Bicêtre, France., Frost AE; Baylor College of Medicine, Houston, TX, USA., Farber HW; Boston University School of Medicine, Boston, MA, USA., Humbert M; Université Paris-Sud, CHU de Bicêtre, INSERM U999, Le Kremlin Bicêtre, France Both authors contributed equally., McGoon MD; Mayo Clinic, Rochester, MN, USA Both authors contributed equally.

Publikováno v: The European respiratory journal [Eur Respir J] 2015 Jul; Vol. 46 (1), pp. 152-64. Date of Electronic Publication: 2015 Apr 02.

Zobrazit plný text záznamu

Akademický článek

Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.

Autor: Simonneau G; Service de Pneumologie, Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France. Electronic address: gerald.simonneau@abc.ap-hop-paris.fr., Galiè N; Institute of Cardiology, University of Bologna, Bologna, Italy., Jansa P; Charles University, 1st Faculty of Medicine, 2nd Medical Department, Clinical Department of Cardiology and Angiology, Prague, Czech Republic., Meyer GM; Complexo Hospitalar Sta Casa de Porto Alegre, Porto Alegre, Brazil., Al-Hiti H; Institute of Clinical and Experimental Medicine-IKEM, Department of Cardiology, Prague, Czech Republic., Kusic-Pajic A; Clinical Development, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland., Lemarié JC; Effi-Stat, Paris, France., Hoeper MM; Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany., Rubin LJ; Division of Pulmonary & Critical Care Medicine, University of California, San Diego, CA, USA.

Publikováno v: International journal of cardiology [Int J Cardiol] 2014 Mar 15; Vol. 172 (2), pp. 332-9. Date of Electronic Publication: 2014 Jan 09.

Zobrazit plný text záznamu

Akademický článek

EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.

Autor: Sitbon O; Université Paris-Sud, INSERM U999, Centre de Référence de l'Hypertension Pulmonaire Sévère, Service Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, Paris, France. Electronic address: olivier.sitbon@bct.aphp.fr., Delcroix M; Department of Pneumology, University Hospital of Leuven, Leuven, Belgium., Bergot E; Centre de Compétence de l'Hypertension Pulmonaire Sévère, Service de Pneumologie, CHU Caen, Université Caen UMR 1086, Caen, France., Boonstra AB; Department of Pulmonology, VU University Medical Center, Amsterdam, The Netherlands., Granton J; Pulmonary Hypertension Programme at UHN, University of Toronto, Toronto, Canada., Langleben D; Center for Pulmonary Vascular Disease, Division of Cardiology, Jewish General Hospital, McGill University, Montreal, Canada., Subías PE; Unidad de Hipertensión Pulmonar, Servicio de Cardiología, Madrid, Spain., Galiè N; Institute of Cardiology, University of Bologna, Bologna, Italy., Pfister T; Department of Clinical Science, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland., Lemarié JC; Effi-stat, Paris, France., Simonneau G; Université Paris-Sud, INSERM U999, Centre de Référence de l'Hypertension Pulmonaire Sévère, Service Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, Paris, France.

Publikováno v: American heart journal [Am Heart J] 2014 Feb; Vol. 167 (2), pp. 210-7. Date of Electronic Publication: 2013 Oct 03.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání